EpiAxis confirms epiresatide as a first-in-class CoRest Complex Disruptor
EpiAxis Therapeutics (EpiAxis) is pleased to announce that newly completed research confirms its lead compound epiresatide has a novel mode of action as a first-in-class CoRest Complex Disruptor. Epiresatide has been specifically designed using AI to address the...
EpiAxis presents at Venture & Capital Singapore
EpiAxis CEO Dr Jeremy Chrisp recently presented at Wholesale Investor's Venture and Capital 2023, an exclusive conference designed to empower high-net-worth VCs, family offices and professional investors with access to investment opportunities and networking. Venture...
EpiAxis heads to Venture & Capital Sydney investor conference
EpiAxis Therapeutics is delighted to announce its participation in the Venture & Capital Sydney investor conference, scheduled for Thursday, 3 August 2023. The event will be held at Hilton Sydney, located at 488 George St, Sydney NSW, from 9am to 6pm. This...
There is currently no therapy to fight recurrent, metastatic breast cancer, which is the major source of death in women with breast cancer. Furthermore, current first-line treatments have extensive side-effects.We are determined to fix that.
Professor Sudha Rao
Founder at EpiAxis Therapeutics